Therapeutic Asset Ratings
462 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
zg2001 tosilate tablets
Neoplasm
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1/2
CC
(40)
ak119
Neoplasm
Akeso
P1
C
(39)
am003
Neoplasm
Aummune Ltd.
P1
C
(39)
Asca101
Neoplasm
MetaFines
P1
C
(39)
asn004
Neoplasm
Kirilys Therapeutics Inc.
P1
C
(39)
Byon3521
Neoplasm
Byondis B.V.
P1
C
(39)
dt2216
Neoplasm
Dialectic Therapeutics, Inc
P1
C
(39)
dz-002
Neoplasm
Da Zen Theranostics Inc
P1
C
(39)
Evorpacept
Solid Tumor
QuantumLeap Healthcare Collaborative
P1
C
(39)
Fuzuloparib
Neoplasm
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(39)
hcw9218
Neoplasm
Masonic Cancer Center, University of Minnesota
P1
C
(39)
hh-101
Neoplasm
Huahui Health
P1
C
(39)
ibi325
Neoplasm
Shandong Cancer Hospital and Institute
P1
C
(39)
Igm-7354
Neoplasm
IGM Biosciences, Inc.
P1
C
(39)
lp-118
Neoplasm
Guangzhou Lupeng Pharmaceutical Company LTD.
P1
C
(39)
rp12146
Neoplasm
Rhizen Pharmaceuticals SA
P1
C
(39)
s095029
Neoplasm
Institut de Recherches Internationales Servier
P1
C
(39)
Sail66
Neoplasm
Chugai Pharmaceutical
P1
C
(39)
snk02
Neoplasm
NKGen Biotech, Inc.
P1
C
(39)
Tuvusertib
Neoplasm
Institut Curie
P1
C
(39)
YH 001
Neoplasm
Eucure (Beijing) Biopharma Co., Ltd
P1
C
(39)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Neoplasm
Eucure (Beijing) Biopharma Co., Ltd
P1
C
(39)
Yzj-5053 Tablets
Neoplasm
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
P1
C
(39)
plx038
Neoplasm
Institut Curie
P1
C
(38)
Zn-C3
Neoplasm
M.D. Anderson Cancer Center
P1
C
(38)
Showing 226 to 250 of 462 assets
Previous
Page 10 of 19
Next
